

Company: Asahi Intecc Co., Ltd.  
Representative: Masahiko Miyata, President & CEO  
(Securities code: 7747, First section of  
Tokyo Stock Exchange and Nagoya Stock Exchange)  
Contact: Mizuho Ito,  
Member of Board & CFO, General Manager of Administration  
(TEL. +81-561-48-5551)

## Notice regarding Memorandum of Understanding with Olympus Corporation on biliary pancreatic endotherapy devices

Asahi Intecc Group announces that Asahi Intecc has concluded a memorandum of understanding with Olympus Corporation that allows Olympus Corporation to sell biliary pancreatic endotherapy devices for gastrointestinal diseases developed and manufactured by Asahi Intecc Group.

### I. Outline of the memorandum of understanding

The endoscopic diagnosis/treatment of gastrointestinal diseases concerning the gallbladder/bile ducts/pancreatic calculi/cysts/cancer is less burdensome on the body compared to open abdominal surgery. As technology advances and expands on a global scale, the performance sought of medical devices used for procedures is also becoming more sophisticated due to expanded adaptation.

Given such circumstances, Asahi Intecc Group is proactively promoting entry into the gastrointestinal field with the medium- to long-term strategy of "Expand affected/treatment area" and "Create new business."

Asahi Intecc Group has developed and manufactured products such as 0.018 "(0.46 mm) small diameter guide wire, which is a biliary pancreatic endotherapy device for gastrointestinal disorders, utilizing technologies cultivated in the cardiovascular field to date, and has concluded a memorandum of understanding with Olympus Corporation through which the company will sell our products. The biliary pancreatic endotherapy devices manufactured by Asahi Intecc are to be introduced first in the Japanese market and in overseas markets in the future.

Olympus Corporation boasts the world's largest market share in gastrointestinal endoscopy and has strong sales capability in the gastrointestinal field. Asahi Intecc Group will strengthen its partnership with Olympus in a wide range of fields, including promoting tie-ups with products other than guide wires in the future. Through these tie-ups, Asahi Intecc Group will strive to disseminate minimally invasive treatment products in a wide range of fields and improve quality of life (QOL) of patients.

- Small diameter 0.018 "(0.46 mm) guide wire

Brand Name : Endoscopic guide wire 2 "Fielder 18"  
Certification Number : 230ADBZX00112000  
Marketing Authorization Holder : ASAHI INTECC Co., Ltd  
Distributed by : Olympus Corporation

Among ERCP (Note 1), a guide wire used for cases using a small diameter catheter. In the future, it is planned to have the guide wire be applicable for EUS (Note 2) as well.

Note 1 ERCP: Endoscopic retrograde cholangiopancreatography

A procedure for inserting a catheter from the exit (papilla) of the bile duct/pancreatic duct in the duodenum, producing a contrast of the bile duct/pancreatic duct, and treating excretion of calculi and excretion of bile.

Note 2 EUS : Endoscopic Ultrasonography

A procedure for observing the bile duct/pancreatic duct from inside the body with an endoscope with an ultrasonic echo device at the tip, diagnosing through the collection of tissue, and treating from inside the body in cases where performing an ERCP is difficult.

## II. Schedule

- Date of resolution of the board of directors : February 13, 2019
- Date of conclusion of contract : February 13, 2019

## III. Summary of Olympus

Company Name : Olympus Corporation  
Representative : Mr. Hiroyuki Sasa, President and Representative Director  
Head Office : Shinjuku Monolith, 3-1 Nishi-Shinjuku 2-chome, Shinjuku-ku, Tokyo  
Established : October 12, 1919  
Sales : 786.5 billion yen (Fiscal year ended March 31, 2018, consolidated basis)  
Business Lines : Manufacturing and sales of precision machinery and instruments  
URL : <https://www.olympus-global.com/>

## IV. Impact on Sales Revenue

The impact on the financial results for the fiscal year ending June 2019 will be minimal, and business performance is expected to improve over the medium to long term.